Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEACE1: Abiraterone and Radiotherapy in Metastatic Hormone-Naïve Prostate Cancer
NCT01957436Phase 3Active, not recruiting
- Sponsor
- Unicancer
- Start
- Nov 2013
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, open-label trial of Abiraterone Acetate Tablets (I) in prostate cancer (PCa) (4 arms), sponsored by Unicancer. Primary endpoint: Overall Survival at 9.5 years. Started Nov 2013; status: active, not recruiting.
02
Drugs
Abiraterone Acetate Tablets (I)
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01957436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01957436.